{"transactions":[{"id":729030,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2026-06-23T21:14:03.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":3000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000083","document":"wk-form4_1782249240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000083/wk-form4_1782249240.xml","form_type":"4"}},{"id":729029,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance share units","published_at":"2026-06-23T21:14:03.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":9000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000083","document":"wk-form4_1782249240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000083/wk-form4_1782249240.xml","form_type":"4"}},{"id":814399,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance share units","published_at":"2026-04-06T20:08:56.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":8500,"derivative":{"underlying":"Common stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001439222-26-000063","document":"wk-form4_1775506133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000063/wk-form4_1775506133.xml","form_type":"4"}},{"id":814398,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:08:56.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":3141,"price":34.71,"value":109024.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024."}],"balance_after":54998,"source":{"system":"sec-edgar","filing":"0001439222-26-000063","document":"wk-form4_1775506133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000063/wk-form4_1775506133.xml","form_type":"4"}},{"id":814397,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:08:56.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 311 shares purchased through the Company's employee stock purchase plan."}],"balance_after":58139,"source":{"system":"sec-edgar","filing":"0001439222-26-000063","document":"wk-form4_1775506133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000063/wk-form4_1775506133.xml","form_type":"4"}},{"id":866577,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":5303,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":10607,"derivative":{"underlying":"Common stock","underlying_shares":5303},"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866576,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":8000,"derivative":{"underlying":"Common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866575,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":5666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":5667,"derivative":{"underlying":"Common stock","underlying_shares":5666},"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866574,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866573,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock options (right to buy)","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":52000,"derivative":{"exercise_price":30.23,"expiration_date":"2036-03-01","underlying":"Common stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866572,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":14000,"derivative":{"underlying":"Common stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866571,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1573,"price":28.96,"value":45554.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025."}],"balance_after":49328,"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866570,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":5303,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50901,"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866569,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1187,"price":28.96,"value":34375.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025."}],"balance_after":45598,"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866568,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":46785,"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866567,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1681,"price":28.96,"value":48681.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024."}],"balance_after":42785,"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866566,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":5666,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":44466,"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866565,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":594,"price":28.96,"value":17202.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023."}],"balance_after":38800,"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":866564,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:14:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":39394,"source":{"system":"sec-edgar","filing":"0001439222-26-000038","document":"wk-form4_1772572487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000038/wk-form4_1772572487.xml","form_type":"4"}},{"id":955117,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance share units","published_at":"2026-01-03T01:14:27.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001439222-26-000002","document":"wk-form4_1767402864.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000002/wk-form4_1767402864.xml","form_type":"4"}},{"id":955116,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-01-03T01:14:27.000Z","date":"2025-12-30","kind":"sale","planned":true,"acquired":false,"shares":2932,"price":27.09,"value":79427.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023."}],"balance_after":37394,"source":{"system":"sec-edgar","filing":"0001439222-26-000002","document":"wk-form4_1767402864.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000002/wk-form4_1767402864.xml","form_type":"4"}},{"id":955115,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-01-03T01:14:27.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 456 shares purchased through the Company's employee stock purchase plan."}],"balance_after":40326,"source":{"system":"sec-edgar","filing":"0001439222-26-000002","document":"wk-form4_1767402864.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000002/wk-form4_1767402864.xml","form_type":"4"}},{"id":1030515,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2025-09-30T21:56:01.000Z","date":"2025-09-26","kind":"exercise","planned":true,"acquired":false,"shares":7472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":7472},"source":{"system":"sec-edgar","filing":"0001439222-25-000104","document":"wk-form4_1759269358.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000104/wk-form4_1759269358.xml","form_type":"4"}},{"id":1030514,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-09-30T21:56:01.000Z","date":"2025-09-26","kind":"sale","planned":true,"acquired":false,"shares":3651,"price":36.77,"value":134247.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated September 26, 2022."}],"balance_after":33870,"source":{"system":"sec-edgar","filing":"0001439222-25-000104","document":"wk-form4_1759269358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000104/wk-form4_1759269358.xml","form_type":"4"}},{"id":1030513,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-09-30T21:56:01.000Z","date":"2025-09-26","kind":"exercise","planned":true,"acquired":true,"shares":7472,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":37521,"source":{"system":"sec-edgar","filing":"0001439222-25-000104","document":"wk-form4_1759269358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000104/wk-form4_1759269358.xml","form_type":"4"}},{"id":1101013,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance share units","published_at":"2025-06-26T21:24:40.000Z","date":"2025-06-24","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":6000,"derivative":{"underlying":"Common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001439222-25-000067","document":"wk-form4_1750973073.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000067/wk-form4_1750973073.xml","form_type":"4"}},{"id":1101012,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-06-26T21:24:40.000Z","date":"2025-06-24","kind":"sale","planned":true,"acquired":false,"shares":1780,"price":33.54,"value":59701.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023."}],"balance_after":30049,"source":{"system":"sec-edgar","filing":"0001439222-25-000067","document":"wk-form4_1750973073.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000067/wk-form4_1750973073.xml","form_type":"4"}},{"id":1101011,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-06-26T21:24:40.000Z","date":"2025-06-24","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":31829,"source":{"system":"sec-edgar","filing":"0001439222-25-000067","document":"wk-form4_1750973073.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000067/wk-form4_1750973073.xml","form_type":"4"}},{"id":1227881,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:15:12.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":false,"shares":5667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":11333,"derivative":{"underlying":"Common stock","underlying_shares":5667},"source":{"system":"sec-edgar","filing":"0001439222-25-000019","document":"wk-form4_1741122903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000019/wk-form4_1741122903.xml","form_type":"4"}},{"id":1227880,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:15:12.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":2000,"derivative":{"underlying":"Common stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001439222-25-000019","document":"wk-form4_1741122903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000019/wk-form4_1741122903.xml","form_type":"4"}},{"id":1227879,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock options (right to buy)","published_at":"2025-03-04T21:15:12.000Z","date":"2025-03-01","kind":"grant","planned":true,"acquired":true,"shares":43500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 1, 2025. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":43500,"derivative":{"exercise_price":35.54,"expiration_date":"2035-03-01","underlying":"Common stock","underlying_shares":43500},"source":{"system":"sec-edgar","filing":"0001439222-25-000019","document":"wk-form4_1741122903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000019/wk-form4_1741122903.xml","form_type":"4"}},{"id":1227878,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:15:12.000Z","date":"2025-03-01","kind":"grant","planned":true,"acquired":true,"shares":15910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":15910,"derivative":{"underlying":"Common stock","underlying_shares":15910},"source":{"system":"sec-edgar","filing":"0001439222-25-000019","document":"wk-form4_1741122903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000019/wk-form4_1741122903.xml","form_type":"4"}},{"id":1227877,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:15:12.000Z","date":"2025-03-01","kind":"grant","planned":true,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":12000,"derivative":{"underlying":"Common stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001439222-25-000019","document":"wk-form4_1741122903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000019/wk-form4_1741122903.xml","form_type":"4"}},{"id":1227876,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:15:12.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":1681,"price":35.54,"value":59742.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024."}],"balance_after":25829,"source":{"system":"sec-edgar","filing":"0001439222-25-000019","document":"wk-form4_1741122903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000019/wk-form4_1741122903.xml","form_type":"4"}},{"id":1227875,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:15:12.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":true,"shares":5667,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":27510,"source":{"system":"sec-edgar","filing":"0001439222-25-000019","document":"wk-form4_1741122903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000019/wk-form4_1741122903.xml","form_type":"4"}},{"id":1227874,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:15:12.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":594,"price":35.54,"value":21110.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023."}],"balance_after":21843,"source":{"system":"sec-edgar","filing":"0001439222-25-000019","document":"wk-form4_1741122903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000019/wk-form4_1741122903.xml","form_type":"4"}},{"id":1227873,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:15:12.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 279 shares purchased through the Company's employee stock purchase plan."}],"balance_after":22437,"source":{"system":"sec-edgar","filing":"0001439222-25-000019","document":"wk-form4_1741122903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000019/wk-form4_1741122903.xml","form_type":"4"}},{"id":1397858,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2024-09-30T20:15:29.000Z","date":"2024-09-26","kind":"exercise","planned":true,"acquired":false,"shares":7473,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":7472,"derivative":{"underlying":"Common stock","underlying_shares":7473},"source":{"system":"sec-edgar","filing":"0001439222-24-000129","document":"wk-form4_1727727323.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000129/wk-form4_1727727323.xml","form_type":"4"}},{"id":1397857,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2024-09-30T20:15:29.000Z","date":"2024-09-26","kind":"sale","planned":true,"acquired":false,"shares":2542,"price":49.03,"value":124634.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated September 26, 2022."}],"balance_after":20158,"source":{"system":"sec-edgar","filing":"0001439222-24-000129","document":"wk-form4_1727727323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000129/wk-form4_1727727323.xml","form_type":"4"}},{"id":1397856,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2024-09-30T20:15:29.000Z","date":"2024-09-26","kind":"exercise","planned":true,"acquired":true,"shares":7473,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,329 shares purchased through the Company's employee stock purchase plan."}],"balance_after":22700,"source":{"system":"sec-edgar","filing":"0001439222-24-000129","document":"wk-form4_1727727323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000129/wk-form4_1727727323.xml","form_type":"4"}},{"id":1595546,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2024-03-05T21:18:08.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":4000,"derivative":{"underlying":"Common stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001439222-24-000052","document":"wk-form4_1709673462.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000052/wk-form4_1709673462.xml","form_type":"4"}},{"id":1595545,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock options (right to buy)","published_at":"2024-03-05T21:18:08.000Z","date":"2024-03-01","kind":"grant","planned":true,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":60000,"derivative":{"exercise_price":32.27,"expiration_date":"2034-03-01","underlying":"Common stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001439222-24-000052","document":"wk-form4_1709673462.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000052/wk-form4_1709673462.xml","form_type":"4"}},{"id":1595544,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2024-03-05T21:18:08.000Z","date":"2024-03-01","kind":"grant","planned":true,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":17000,"derivative":{"underlying":"Common stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001439222-24-000052","document":"wk-form4_1709673462.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000052/wk-form4_1709673462.xml","form_type":"4"}},{"id":1595543,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2024-03-05T21:18:08.000Z","date":"2024-03-05","kind":"sale","planned":true,"acquired":false,"shares":672,"price":32.57,"value":21887.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023."}],"balance_after":14840,"source":{"system":"sec-edgar","filing":"0001439222-24-000052","document":"wk-form4_1709673462.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000052/wk-form4_1709673462.xml","form_type":"4"}},{"id":1595542,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2024-03-05T21:18:08.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 942 shares purchased through the Company's employee stock purchase plan."}],"balance_after":15512,"source":{"system":"sec-edgar","filing":"0001439222-24-000052","document":"wk-form4_1709673462.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000052/wk-form4_1709673462.xml","form_type":"4"}},{"id":1671973,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance share units","published_at":"2024-01-24T21:23:19.000Z","date":"2024-01-20","kind":"exercise","planned":true,"acquired":false,"shares":5380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on September 26, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on September 26, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":5380},"source":{"system":"sec-edgar","filing":"0001439222-24-000018","document":"wk-form4_1706131387.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000018/wk-form4_1706131387.xml","form_type":"4"}},{"id":1671972,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2024-01-24T21:23:19.000Z","date":"2024-01-24","kind":"sale","planned":true,"acquired":false,"shares":1886,"price":21.64,"value":40813.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated September 26, 2022."}],"balance_after":13069,"source":{"system":"sec-edgar","filing":"0001439222-24-000018","document":"wk-form4_1706131387.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000018/wk-form4_1706131387.xml","form_type":"4"}},{"id":1671971,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2024-01-24T21:23:19.000Z","date":"2024-01-20","kind":"exercise","planned":true,"acquired":true,"shares":5380,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14955,"source":{"system":"sec-edgar","filing":"0001439222-24-000018","document":"wk-form4_1706131387.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000018/wk-form4_1706131387.xml","form_type":"4"}},{"id":1772086,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2023-09-28T20:02:49.000Z","date":"2023-09-26","kind":"exercise","planned":true,"acquired":false,"shares":7472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":14945,"derivative":{"underlying":"Common stock","underlying_shares":7472},"source":{"system":"sec-edgar","filing":"0001439222-23-000133","document":"wk-form4_1695931360.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000133/wk-form4_1695931360.xml","form_type":"4"}},{"id":1772085,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2023-09-28T20:02:49.000Z","date":"2023-09-28","kind":"sale","planned":true,"acquired":false,"shares":2179,"price":24.79,"value":54017.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act.  Such instructions were included in the reporting person's restricted stock unit agreement dated 9/28/23."}],"balance_after":9575,"source":{"system":"sec-edgar","filing":"0001439222-23-000133","document":"wk-form4_1695931360.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000133/wk-form4_1695931360.xml","form_type":"4"}},{"id":1772084,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2023-09-28T20:02:49.000Z","date":"2023-09-26","kind":"exercise","planned":true,"acquired":true,"shares":7472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 499 shares purchased through the Company's employee stock purchase plan."}],"balance_after":11754,"source":{"system":"sec-edgar","filing":"0001439222-23-000133","document":"wk-form4_1695931360.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000133/wk-form4_1695931360.xml","form_type":"4"}},{"id":1841014,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance share units","published_at":"2023-06-30T20:03:58.000Z","date":"2023-06-28","kind":"exercise","planned":true,"acquired":false,"shares":5380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":5380,"derivative":{"underlying":"Common stock","underlying_shares":5380},"source":{"system":"sec-edgar","filing":"0001439222-23-000101","document":"wk-form4_1688155416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000101/wk-form4_1688155416.xml","form_type":"4"}},{"id":1841013,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2023-06-30T20:03:58.000Z","date":"2023-06-30","kind":"sale","planned":true,"acquired":false,"shares":1597,"price":28.36,"value":45290.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units."}],"balance_after":3783,"source":{"system":"sec-edgar","filing":"0001439222-23-000101","document":"wk-form4_1688155416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000101/wk-form4_1688155416.xml","form_type":"4"}},{"id":1841012,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2023-06-30T20:03:58.000Z","date":"2023-06-28","kind":"exercise","planned":true,"acquired":true,"shares":5380,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5380,"source":{"system":"sec-edgar","filing":"0001439222-23-000101","document":"wk-form4_1688155416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000101/wk-form4_1688155416.xml","form_type":"4"}},{"id":1972881,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock options (right to buy)","published_at":"2023-03-03T21:07:24.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":22000,"derivative":{"exercise_price":25.01,"expiration_date":"2033-03-01","underlying":"Common stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001439222-23-000050","document":"wf-form4_167787761251341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000050/wf-form4_167787761251341.xml","form_type":"4"}},{"id":1972880,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2023-03-03T21:07:24.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on  March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on  March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":6000,"derivative":{"underlying":"Common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001439222-23-000050","document":"wf-form4_167787761251341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000050/wf-form4_167787761251341.xml","form_type":"4"}},{"id":2149875,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2022-09-28T20:10:56.000Z","date":"2022-09-26","kind":"grant","acquired":true,"shares":22417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on September 26, 2022. Beginning on September 26, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":22417,"derivative":{"underlying":"Common stock","underlying_shares":22417},"source":{"system":"sec-edgar","filing":"0001439222-22-000089","document":"wf-form4_166439584185254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000089/wf-form4_166439584185254.xml","form_type":"4"}},{"id":2149874,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock options (right to buy)","published_at":"2022-09-28T20:10:56.000Z","date":"2022-09-26","kind":"grant","acquired":true,"shares":118390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on September 26, 2022. The shares underlying this option vest as to 25% of the underlying shares on September 26, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":118390,"derivative":{"exercise_price":27.88,"expiration_date":"2032-09-26","underlying":"Common stock","underlying_shares":118390},"source":{"system":"sec-edgar","filing":"0001439222-22-000089","document":"wf-form4_166439584185254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000089/wf-form4_166439584185254.xml","form_type":"4"}},{"id":2352483,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-03T18:05:02.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":112000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The options were granted by LogicBio Therapeutics, Inc. (the \"Company\") pursuant to its 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date."}],"balance_after":112000,"derivative":{"exercise_price":0.7,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":112000},"source":{"system":"sec-edgar","filing":"0001209191-22-015795","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664106/000120919122015795/doc4.xml","form_type":"4"}},{"id":2435638,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-13T18:36:54.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":5939,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the \"Company\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs, which represent 100% of the RSUs granted to the Reporting Person that were previously reported for the Reporting Person on a Form 4 filed on January 13, 2021, vested on January 11, 2022, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs, which represent 100% of the RSUs granted to the Reporting Person that were previously reported for the Reporting Person on a Form 4 filed on January 13, 2021, vested on January 11, 2022, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5939},"source":{"system":"sec-edgar","filing":"0001209191-22-003250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1664106/000120919122003250/doc4.xml","form_type":"4"}},{"id":2435637,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-13T18:36:54.000Z","date":"2022-01-12","kind":"tax_withholding","acquired":false,"shares":2175,"price":2.01,"value":4371.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This sale was made automatically by the Company to cover tax withholding obligations in connection with the vesting and settlement of the RSUs reported in the row above. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.03, inclusive."}],"balance_after":3764,"source":{"system":"sec-edgar","filing":"0001209191-22-003250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1664106/000120919122003250/doc4.xml","form_type":"4"}},{"id":2435636,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-13T18:36:54.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":5939,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the \"Company\")."}],"balance_after":5939,"source":{"system":"sec-edgar","filing":"0001209191-22-003250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664106/000120919122003250/doc4.xml","form_type":"4"}},{"id":2831851,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-25T19:00:37.000Z","date":"2021-02-23","kind":"grant","acquired":true,"shares":78000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% vests on 01/11/2022 and the remainder vests in equal monthly installments over the next 36 months."}],"balance_after":78000,"derivative":{"exercise_price":7.76,"expiration_date":"2031-02-23","underlying":"Common Stock","underlying_shares":78000},"source":{"system":"sec-edgar","filing":"0001209191-21-014476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664106/000120919121014476/doc4.xml","form_type":"4"}},{"id":2907907,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-01-13T19:10:08.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":5939,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of LogicBio Therapeutics Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will fully vest on January 11, 2022, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan; provided, that if the reporting person's employment is terminated by the Company without \"cause\" or by the reporting person for \"good reason\" (as defined in the reporting person's employment agreement) prior to January 11, 2022, all such RSUs will vest on the date of termination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will fully vest on January 11, 2022, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan; provided, that if the reporting person's employment is terminated by the Company without \"cause\" or by the reporting person for \"good reason\" (as defined in the reporting person's employment agreement) prior to January 11, 2022, all such RSUs will vest on the date of termination."}],"balance_after":5939,"derivative":{"underlying":"Common Stock","underlying_shares":5939},"source":{"system":"sec-edgar","filing":"0001209191-21-003473","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1664106/000120919121003473/doc4.xml","form_type":"4"}},{"id":2907906,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-13T19:10:08.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% vests on 01/11/2022 and the remainder vests in equal monthly installments over the next 36 months."}],"balance_after":195000,"derivative":{"exercise_price":8.42,"expiration_date":"2031-01-11","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001209191-21-003473","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664106/000120919121003473/doc4.xml","form_type":"4"}}]}